Search

Your search keyword '"Shah, Neil J."' showing total 195 results
Start Over Author "Shah, Neil J."
195 results on '"Shah, Neil J."'

3. The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer

Author

Shah, Neil J, Patel, Vaibhav G, Zhong, Xiaobo, Pina, Luis, Hawley, Jessica E, Lin, Emily, Gartrell, Benjamin A, Febles, Victor Adorno, Wise, David R, Qin, Qian, Mellgard, George, Joshi, Himanshu, Nauseef, Jones T, Green, David A, Vlachostergios, Panagiotis J, Kwon, Daniel H, Huang, Franklin, Liaw, Bobby, Tagawa, Scott, Kantoff, Philip, Morris, Michael J, and Oh, William K

Subjects
Aging, Urologic Diseases, Patient Safety, Clinical Research, Prevention, Cancer, Prostate Cancer, Lung, Good Health and Well Being, Aged, Androgen Antagonists, Androgens, COVID-19, COVID-19 Testing, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, Retrospective Studies, SARS-CoV-2, COVID-19 Drug Treatment
Abstract

BackgroundTMPRSS2, a cell surface protease regulated by androgens and commonly upregulated in prostate cancer (PCa), is a necessary component for SARS-CoV-2 viral entry into respiratory epithelial cells. Previous reports suggested a lower risk of SARS-CoV-2 among PCa patients on androgen deprivation therapy (ADT). However, the impact of ADT on severe COVID-19 illness is poorly understood.MethodsWe performed a multicenter study across 7 US medical centers and evaluated patients with PCa and SARS-CoV-2 detected by polymerase-chain-reaction between March 1, 2020, and May 31, 2020. PCa patients were considered on ADT if they had received appropriate ADT treatment within 6 months of COVID-19 diagnosis. We used multivariable logistic and Cox proportional-hazard regression models for analysis. All statistical tests were 2-sided.ResultsWe identified 465 PCa patients (median age = 71 years) with a median follow-up of 60 days. Age, body mass index, cardiovascular comorbidity, and PCa clinical disease state adjusted overall survival (hazard ratio [HR] = 1.16, 95% confidence interval [CI] = 0.68 to 1.98, P = .59), hospitalization status (HR = 0.96, 95% CI = 0.52 to 1.77, P = .90), supplemental oxygenation (HR 1.14, 95% CI = 0.66 to 1.99, P = .64), and use of mechanical ventilation (HR = 0.81, 95% CI = 0.25 to 2.66, P = .73) were similar between ADT and non-ADT cohorts. Similarly, the addition of androgen receptor-directed therapy within 30 days of COVID-19 diagnosis to ADT vs ADT alone did not statistically significantly affect overall survival (androgen receptor-directed therapy: HR = 1.27, 95% CI = 0.69 to 2.32, P = .44).ConclusionsIn this retrospective cohort of PCa patients, the use of ADT was not demonstrated to influence severe COVID-19 outcomes, as defined by hospitalization, supplemental oxygen use, or death. Age 70 years and older was statistically significantly associated with a higher risk of developing severe COVID-19 disease.

Published
2022

4. Esophagectomy may have a role in stage IV esophageal adenocarcinoma

Author

Sewell, Marisa, Toumbacaris, Nicolas, Tan, Kay See, Bahadur, Nadia, Philip, John, Shah, Neil J., Niederhausern, Andrew, Tavarez Martinez, Carlos, Zheng, Haiyu, Boerner, Thomas, Janjigian, Yelena Y., Maron, Steve B., Bott, Matthew J., Gray, Katherine D., Park, Bernard J., Sihag, Smita, Jones, David R., Ku, Geoffrey Y., Wu, Abraham J., and Molena, Daniela

Published
2024
Full Text
View/download PDF

5. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.

Author

Gul, Anita, Stewart, Tyler F, Mantia, Charlene M, Shah, Neil J, Gatof, Emily Stern, Long, Ying, Allman, Kimberly D, Ornstein, Moshe C, Hammers, Hans J, McDermott, David F, Atkins, Michael B, Hurwitz, Michael, and Rini, Brian I

Subjects
Kidney Disease, Cancer, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Carcinoma, Renal Cell, Disease Progression, Female, Humans, Immune Checkpoint Inhibitors, Ipilimumab, Kidney Neoplasms, Male, Middle Aged, Nivolumab, Programmed Cell Death 1 Receptor, Progression-Free Survival, Retreatment, Retrospective Studies, Salvage Therapy, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeImmune checkpoint inhibitors (ICIs) are standard therapy in metastatic renal cell carcinoma (RCC). The safety and activity of the combination of ipilimumab and nivolumab in patients who have received prior ICI targeting the programmed death 1 (PD-1) pathway remains unknown. We evaluated ipilimumab and nivolumab in patients with metastatic RCC after prior treatment with anti-PD-1 pathway-targeted therapy.Patients and methodsPatients with metastatic RCC who received prior anti-PD-1 pathway-targeted therapy and subsequently received ipilimumab and nivolumab were reviewed. Objective response rate and progression-free survival per investigator assessment were recorded. Toxicity of ipilimumab and nivolumab was also assessed.ResultsForty-five patients with metastatic RCC were included. All patients (100%) received prior ICIs targeting the PD-1 pathway. The median age was 62 years (range, 21-82 years). At a median follow-up of 12 months, the objective response rate to ipilimumab and nivolumab was 20%. The median progression-free survival while on ipilimumab and nivolumab was 4 months (range, 0.8-19 months). Immune-related adverse events (irAEs) of any grade with ipilimumab and nivolumab were recorded in 29 (64%) of the 45 patients; grade 3 irAEs were recorded in 6 (13%) of the 45 patients.ConclusionIpilimumab and nivolumab demonstrated antitumor activity with acceptable toxicity in patients with metastatic RCC who had prior treatment with checkpoint inhibition.

Published
2020

8. Patient-reported experience with an immunotherapy telehealth platform.

Author

Daly, Robert Michael, primary, Bange, Erin Mary, additional, Doshi, Sahil D, additional, Li, Bob T., additional, Shah, Neil J., additional, Aggen, David H, additional, Kotecha, Ritesh R, additional, Eng, Juliana, additional, Ng, Kenneth K., additional, Polubriaginof, Fernanda C. G., additional, Kuperman, Gilad, additional, Lipitz-Snyderman, Allison, additional, Stetson, Peter D., additional, Schrag, Deb, additional, Panageas, Katherine, additional, and Morris, Michael J., additional

Published
2024
Full Text
View/download PDF

9. Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial

Author

Fitzgerald, Kelly N., primary, Lee, Chung-Han, additional, Voss, Martin H., additional, Carlo, Maria I., additional, Knezevic, Andrea, additional, Peralta, Laura, additional, Chen, Yingbei, additional, Lefkowitz, Robert A., additional, Shah, Neil J., additional, Owens, Colette N., additional, McHugh, Deaglan J., additional, Aggen, David H., additional, Laccetti, Andrew L., additional, Kotecha, Ritesh R., additional, Feldman, Darren R., additional, and Motzer, Robert J., additional

Published
2024
Full Text
View/download PDF

19. Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma

Author

Kotecha, Ritesh R., Gedvilaite, Erika, Ptashkin, Ryan, Knezevic, Andrea, Murray, Samuel, Johnson, Ian, Shapnik, Natalie, Feldman, Darren R., Carlo, Maria I., Shah, Neil J., Dunigan, Marisa, Huberman, Kety, Benayed, Ryma, Zehir, Ahmet, Berger, Michael F., Ladanyi, Marc, Tsui, Dana W. Y., Motzer, Robert J., Lee, Chung-Han, and Voss, Martin H.

Published
2022
Full Text
View/download PDF

20. Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials.

Author

Shah, Neil J., Della Pia, Alexandra, Wu, Tianmin, Williams, Aquino, Weber, Melinda, Sinclaire, Brittany, Gourna Paleoudis, Elli, Alaoui, Adil, Lev-Ari, Shaked, Adams, Shari, Kaufman, Jordan, Parikh, Sahil B., Tonti, Emily, Muller, Eric, Serzan, Michael, Cheruku, Divya, Lee, Albert, Sridhar, Aishwarya, Hee, Benjamin Perrin, and Ahn, Jaeil

Subjects
*PATIENT safety, *CLINICAL trials, *SMOKING, *TREATMENT effectiveness, *IMMUNE system, *RETROSPECTIVE studies, *WHITE people, *MULTIVARIATE analysis, *IMMUNE checkpoint inhibitors, *CELL lines, *BLACK people, *DRUG efficacy, *AUTOIMMUNE diseases, *STATISTICS, *LUNG cancer, *VIRUS diseases, *TREATMENT failure, *NIVOLUMAB, *OVERALL survival, *OBESITY
Abstract

Simple Summary: Immune checkpoint inhibitors (ICIs) are a type of immunotherapy used to treat a variety of cancers by helping a patient's own immune system to kill cancer cells. ICIs received their regulatory approval based on the results of large, randomized clinical trials. However, certain patient groups were excluded from these trials, so their outcomes are unknown. We performed a multicenter, retrospective study of real-world data in the United States in patients who had received at least one cycle of ICI treatment to evaluate the efficacy and safety of ICIs in patient groups underrepresented in clinical trials. Unique patient groups included age > 75 years, non-White race, positive smoking history, poor performance status, obesity, autoimmune diseases, chronic viral infections, multiple previous cancer therapies, or >three metastatic sites. Overall, ICIs were safe and efficacious in these patient groups. We noted that poor performance status and a history of multiple cancer therapies were associated with poor ICI efficacy, and Black patients, compared to White patients, experienced fewer immune-related adverse events. Regulatory approval of immune checkpoint inhibitors (ICIs) was based on results of large, randomized clinical trials, resulting in limited outcomes data in patient cohorts typically underrepresented in such trials. The objective of this study was to evaluate the efficacy and safety of ICIs in these unique patient cohorts. This is a multicenter, retrospective analysis of real-world data at six academic and community clinics in the United States from 1 January 2011 to 1 April 2018. Patients were included if they had received at least one cycle of ICI treatment. Unique patient cohorts included age > 75 years, non-White race, positive smoking history, ECOG performance status (PS) ≥ 2, BMI ≥ 30 kg/m2, autoimmune diseases (AIDs), chronic viral infections (CVI), extensive prior lines of therapy (LOTs), or >three metastatic sites. Immune-related adverse events (irAEs), overall survival (OS), and time to treatment failure were evaluated in the entire cohort and in NSCLC patients treated with PD-(L)1 monotherapy. Outcomes and their association with unique patient cohorts were compared on univariate analysis and multivariate analysis to those without a particular characteristic in the entire NSCLC PD-(L)1 monotherapy cohorts. In total, 1453 patients were included: 56.5%—smokers, 30.4%—non-White, 22.8%—elderly, 20.8%—ECOG PS ≥ 2, 15.7%—history of AIDs, and 4.7%—history of CVI. The common ICIs were nivolumab (37.1%) and pembrolizumab (22.2%). Black patients, compared to White patients, experienced fewer irAEs (OR 0.54, p < 0.001). An ECOG PS of ≥2 (HR = 2.01, p < 0.001) and an increased number of previous LOTs were associated with poor OS (the median OS of 26.2 vs. 16.2 vs. 9.6 months for one vs. two vs. three prior LOTs, p < 0.001). The above results were confirmed in anti-PD-(L)1 monotherapy non-small cell lung cancer patients (n = 384). Overall, ICIs were safe and efficacious in these typically underrepresented patient cohorts. We noted ECOG PS ≥ 2 and an increased prior LOTs were associated with poor ICI efficacy, and Black patients, compared to White patients, experienced fewer irAEs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer

Author

Kotecha, Ritesh R., primary, Doshi, Sahil D., additional, Knezevic, Andrea, additional, Chaim, Joshua, additional, Chen, Yingbei, additional, Jacobi, Rachel, additional, Zucker, Mark, additional, Reznik, Ed, additional, McHugh, Deaglan, additional, Shah, Neil J., additional, Feld, Emily, additional, Aggen, David H., additional, Rafelson, William, additional, Xiao, Han, additional, Carlo, Maria I., additional, Feldman, Darren R., additional, Lee, Chung-Han, additional, Motzer, Robert J., additional, and Voss, Martin H., additional

Published
2023
Full Text
View/download PDF

23. 615 The impact of gender including female menopausal status on the safety and efficacy of immune checkpoint inhibitors

Author

Ari, Shaked Lev, primary, Zaemes, Jacob, additional, Ozisik, Deniz, additional, Zemel, Rachel A, additional, Tan, Ming, additional, Pascual, Lauren, additional, Sinclaire, Brittany, additional, Alaoui, Adil, additional, DellaPia, Alexandra, additional, Pecora, Andrew, additional, Atkins, Michael B, additional, Ip, Andrew, additional, and Shah, Neil J, additional

Published
2023
Full Text
View/download PDF

24. 1244 Polarized immune responses reveal actionable therapeutic targets in cutaneous adverse events to checkpoint inhibitors

Author

Gu, Stephanie, primary, Goleva, Elena, additional, Moy, Andrea P, additional, Ketosugbo, Kwami, additional, Kraehenbuehl, Lukas, additional, Maier, Tara, additional, Salvador, Trina, additional, Shah, Neil J, additional, Weight, Ryan, additional, Rotemberg, Veronica, additional, Kern, Jeffrey A, additional, Leung, Donald Y, additional, and Lacouture, Mario E, additional

Published
2023
Full Text
View/download PDF

25. 1418 Treatment-free survival in patients with advanced melanoma and non-small cell lung cancer receiving immune checkpoint inhibitors: real-world outcomes over a 3-year timespan

Author

Zaemes, Jacob, primary, Ari, Shaked Lev, additional, Pascual, Lauren, additional, Jegede, Opeyemi A, additional, Arias-Orozco, Natali, additional, Sinclaire, Brittany, additional, DellaPia, Alexandra, additional, Zemel, Rachel A, additional, Zhang, Yili, additional, Gupta, Samir, additional, Alaoui, Adil, additional, Ip, Andrew, additional, Atkins, Michael B, additional, Regan, Meredith, additional, and Shah, Neil J, additional

Published
2023
Full Text
View/download PDF

26. Genomic ancestry in kidney cancer: Correlations with clinical and molecular features

Author

Kotecha, Ritesh R., primary, Knezevic, Andrea, additional, Arora, Kanika, additional, Bandlamudi, Chaitanya, additional, Kuo, Fengshen, additional, Carlo, Maria I., additional, Fitzgerald, Kelly N., additional, Feldman, Darren R., additional, Shah, Neil J., additional, Reznik, Ed, additional, Hakimi, A. Ari, additional, Carrot‐Zhang, Jian, additional, Mandelker, Diana, additional, Berger, Michael, additional, Lee, Chung‐Han, additional, Motzer, Robert J., additional, and Voss, Martin H., additional

Published
2023
Full Text
View/download PDF

28. Abstract B022: Clinical outcomes in NF2-mutated RCC treated with contemporary immunotherapy regimens

Author

Fitzgerald, Kelly N., primary, Duzgol, Cihan, additional, Knezevic, Andrea, additional, Jacobi, Rachel, additional, Kotecha, Ritesh R., additional, Aggen, David H., additional, Carlo, Maria I., additional, Shah, Neil J., additional, Voss, Martin H., additional, Feldman, Darren R., additional, Motzer, Robert J., additional, and Lee, Chung-Han, additional

Published
2023
Full Text
View/download PDF

29. Genomic ancestry in kidney cancer: Correlations with clinical and molecular features.

Author

Kotecha, Ritesh R., Knezevic, Andrea, Arora, Kanika, Bandlamudi, Chaitanya, Kuo, Fengshen, Carlo, Maria I., Fitzgerald, Kelly N., Feldman, Darren R., Shah, Neil J., Reznik, Ed, Hakimi, A. Ari, Carrot‐Zhang, Jian, Mandelker, Diana, Berger, Michael, Lee, Chung‐Han, Motzer, Robert J., and Voss, Martin H.

Subjects
RENAL cancer, RENAL cell carcinoma, FISHER exact test, HEALTH equity, GENEALOGY
Abstract

Introduction: Genetic ancestry (GA) refers to population hereditary patterns that contribute to phenotypic differences seen among race/ethnicity groups, and differences among GA groups may highlight unique biological determinants that add to our understanding of health care disparities. Methods: A retrospective review of patients with renal cell carcinoma (RCC) was performed and correlated GA with clinicopathologic, somatic, and germline molecular data. All patients underwent next‐generation sequencing of normal and tumor DNA using Memorial Sloan Kettering‐Integrated Mutation Profiling of Actionable Cancer Targets, and contribution of African (AFR), East Asian (EAS), European (EUR), Native American, and South Asian (SAS) ancestry was inferred through supervised ADMIXTURE. Molecular data was compared across GA groups by Fisher exact test and Kruskal–Wallis test. Results: In 953 patients with RCC, the GA distribution was: EUR (78%), AFR (4.9%), EAS (2.5%), SAS (2%), Native American (0.2%), and Admixed (12.2%). GA distribution varied by tumor histology and international metastatic RCC database consortium disease risk status (intermediate‐poor: EUR 58%, AFR 88%, EAS 74%, and SAS 73%). Pathogenic/likely pathogenic germline variants in cancer‐predisposition genes varied (16% EUR, 23% AFR, 8% EAS, and 0% SAS), and most occurred in CHEK2 in EUR (3.1%) and FH in AFR (15.4%). In patients with clear cell RCC, somatic alteration incidence varied with significant enrichment in BAP1 alterations (EUR 17%, AFR 50%, SAS 29%; p =.01). Comparing AFR and EUR groups within The Cancer Genome Atlas, significant differences were identified in angiogenesis and inflammatory pathways. Conclusion: Differences in clinical and molecular data by GA highlight population‐specific variations in patients with RCC. Exploration of both genetic and nongenetic variables remains critical to optimize efforts to overcome health‐related disparities. This study identifies differences in clinical and molecular data by genetic ancestry and uncovers population‐specific variations that may impact specific patient populations with renal cell carcinoma. Exploration of genetic and nongenetic variables that contribute to these differences are critical to reduce health‐related disparities. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes.

Author

Shah, Neil J., Aggen, David H, Zheng, Junting, Niederhausern, Andrew, Alam, Syed Muneeb, Balar, Om, Bahadur, Nadia, Watson, Adam, Regazzi, Ashley M., Ratna, Neha, Funt, Samuel A, Teo, Min Yuen, Pietzak, Eugene J., Solit, David B., Bajorin, Dean F., Philip, John, Rosenberg, Jonathan E., Ostrovnaya, Irina, Al-Ahmadie, Hikmat A., and Iyer, Gopa

Published
2024
Full Text
View/download PDF

31. HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer.

Author

Aggen, David H, Shah, Neil J., Zheng, Junting, Alam, Syed Muneeb, Balar, Om, Niederhausern, Andrew, Regazzi, Ashley M., Ratna, Neha, Funt, Samuel A, Teo, Min Yuen, Pietzak, Eugene J., Solit, David B., Bajorin, Dean F., Ostrovnaya, Irina, Rosenberg, Jonathan E., Al-Ahmadie, Hikmat A., and Iyer, Gopa

Published
2024
Full Text
View/download PDF

33. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium

Author

El Zarif, Talal, primary, Nassar, Amin H., additional, Adib, Elio, additional, Fitzgerald, Bailey G., additional, Huang, Jiaming, additional, Mouhieddine, Tarek H., additional, Rubinstein, Paul G., additional, Nonato, Taylor, additional, McKay, Rana R., additional, Li, Mingjia, additional, Mittra, Arjun, additional, Owen, Dwight H., additional, Baiocchi, Robert A., additional, Lorentsen, Michael, additional, Dittus, Christopher, additional, Dizman, Nazli, additional, Falohun, Adewunmi, additional, Abdel-Wahab, Noha, additional, Diab, Adi, additional, Bankapur, Anand, additional, Reed, Alexandra, additional, Kim, Chul, additional, Arora, Aakriti, additional, Shah, Neil J., additional, El-Am, Edward, additional, Kozaily, Elie, additional, Abdallah, Wassim, additional, Al-Hader, Ahmad, additional, Abu Ghazal, Batool, additional, Saeed, Anwaar, additional, Drolen, Claire, additional, Lechner, Melissa G., additional, Drakaki, Alexandra, additional, Baena, Javier, additional, Nebhan, Caroline A., additional, Haykal, Tarek, additional, Morse, Michael A., additional, Cortellini, Alessio, additional, Pinato, David J., additional, Dalla Pria, Alessia, additional, Hall, Evan, additional, Bakalov, Veli, additional, Bahary, Nathan, additional, Rajkumar, Aarthi, additional, Mangla, Ankit, additional, Shah, Vishal, additional, Singh, Parminder, additional, Aboubakar Nana, Frank, additional, Lopetegui-Lia, Nerea, additional, Dima, Danai, additional, Dobbs, Ryan W., additional, Funchain, Pauline, additional, Saleem, Rabia, additional, Woodford, Rachel, additional, Long, Georgina V., additional, Menzies, Alexander M., additional, Genova, Carlo, additional, Barletta, Giulia, additional, Puri, Sonam, additional, Florou, Vaia, additional, Idossa, Dame, additional, Saponara, Maristella, additional, Queirolo, Paola, additional, Lamberti, Giuseppe, additional, Addeo, Alfredo, additional, Bersanelli, Melissa, additional, Freeman, Dory, additional, Xie, Wanling, additional, Reid, Erin G., additional, Chiao, Elizabeth Y., additional, Sharon, Elad, additional, Johnson, Douglas B., additional, Ramaswami, Ramya, additional, Bower, Mark, additional, Emu, Brinda, additional, Marron, Thomas U., additional, Choueiri, Toni K., additional, Baden, Lindsey R., additional, Lurain, Kathryn, additional, Sonpavde, Guru P., additional, and Naqash, Abdul Rafeh, additional

Published
2023
Full Text
View/download PDF

36. The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real‐world, multicenter, retrospective study

Author

Lev‐Ari, Shaked, primary, Serzan, Michael, additional, Wu, Tianmin, additional, Ip, Andrew, additional, Pascual, Lauren, additional, Sinclaire, Brittany, additional, Adams, Shari, additional, Marafelias, Michael, additional, Ayyagari, Lakshmi, additional, Gill, Sarvarinder K., additional, Ma, Barbara, additional, Zaemes, Jacob P., additional, Della Pia, Alexandra, additional, Alaoui, Adil, additional, Madhavan, Subha, additional, Belouali, Anas, additional, Pecora, Andrew, additional, Ahn, Jaeil, additional, Atkins, Michael B., additional, and Shah, Neil J., additional

Published
2023
Full Text
View/download PDF

37. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations

Author

Fitzgerald, Kelly N., primary, Duzgol, Cihan, additional, Knezevic, Andrea, additional, Shapnik, Natalie, additional, Kotecha, Ritesh, additional, Aggen, David H., additional, Carlo, Maria I., additional, Shah, Neil J., additional, Voss, Martin H., additional, Feldman, Darren R., additional, Motzer, Robert J., additional, and Lee, Chung-Han, additional

Published
2023
Full Text
View/download PDF

38. Correlating HLA variants and the emergence of immune-related adverse events (irAEs) from ipilimumab/nivolumab (I/N) in patients (pts) treated on CheckMate 214.

Author

Voss, Martin H, primary, Shah, Neil J., additional, Kalvin, Hannah L, additional, Lihm, Jayon, additional, Li, Hao, additional, Kotecha, Ritesh R, additional, Jarchum, Irene, additional, Vemula, Sai Vikram, additional, Gupta, Saurabh, additional, Motzer, Robert J., additional, Ostrovnaya, Irina, additional, Greenbaum, Benjamin, additional, and Hakimi, A. Ari, additional

Published
2023
Full Text
View/download PDF

39. A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC).

Author

Shah, Neil J., primary, Campbell, Matthew T, additional, Mao, Shifeng S., additional, Ornstein, Moshe Chaim, additional, Haas, Naomi B., additional, Gao, Xin, additional, Hammers, Hans J., additional, Keshava-Prasad, Holavanahalli, additional, Yan, Hongxia, additional, Esquibel, Vanessa, additional, Geller, Robert B., additional, and Beckermann, Katy, additional

Published
2023
Full Text
View/download PDF

40. Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations.

Author

Fitzgerald, Kelly N., primary, Duzgol, Cihan, additional, Knezevic, Andrea, additional, Shapnik, Natalie, additional, Kotecha, Ritesh R, additional, Aggen, David H, additional, Carlo, Maria Isabel, additional, Shah, Neil J., additional, Voss, Martin H, additional, Feldman, Darren R., additional, Motzer, Robert J., additional, and Lee, Chung-Han, additional

Published
2023
Full Text
View/download PDF

42. Corrigendum to “Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial” [Eur. Urol. 86(2) (2024) 90–94]

Author

Fitzgerald, Kelly N., Lee, Chung-Han, Voss, Martin H., Carlo, Maria I., Knezevic, Andrea, Peralta, Laura, Chen, Yingbei, Lefkowitz, Robert A., Shah, Neil J., Owens, Colette N., McHugh, Deaglan J., Aggen, David H., Laccetti, Andrew L., Kotecha, Ritesh R., Feldman, Darren R., and Motzer, Robert J.

Published
2025
Full Text
View/download PDF

43. Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13, 6109

Author

Zhang, Dongyu, primary, Shah, Neil J., additional, Cook, Michael, additional, Blackburn, Matthew, additional, Serzan, Michael T., additional, Advani, Shailesh, additional, Potosky, Arnold L., additional, Madhavan, Subha, additional, Belouali, Anas, additional, Atkins, Michael B., additional, and Braithwaite, Dejana, additional

Published
2022
Full Text
View/download PDF

44. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates

Author

Lee, Chung-Han, primary, Voss, Martin H., additional, Carlo, Maria Isabel, additional, Chen, Ying-Bei, additional, Zucker, Mark, additional, Knezevic, Andrea, additional, Lefkowitz, Robert A., additional, Shapnik, Natalie, additional, Dadoun, Chloe, additional, Reznik, Ed, additional, Shah, Neil J., additional, Owens, Colette Ngozi, additional, McHugh, Deaglan Joseph, additional, Aggen, David Henry, additional, Laccetti, Andrew Leonard, additional, Kotecha, Ritesh, additional, Feldman, Darren R., additional, and Motzer, Robert J., additional

Published
2022
Full Text
View/download PDF

47. Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations.

Author

Fitzgerald, Kelly N., primary, Duzgol, Cihan, additional, Knezevic, Andrea, additional, Shapnik, Natalie, additional, Kotecha, Ritesh, additional, Aggen, David Henry, additional, Carlo, Maria Isabel, additional, Shah, Neil J., additional, Voss, Martin H, additional, Feldman, Darren R., additional, Motzer, Robert J., additional, and Lee, Chung-Han, additional

Published
2022
Full Text
View/download PDF

48. A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140).

Author

Shah, Neil J., primary, Beckermann, Katy, additional, Vogelzang, Nicholas J., additional, Mao, Shifeng S., additional, Ornstein, Moshe Chaim, additional, Hammers, Hans J., additional, Gao, Xin, additional, McDermott, David F., additional, Haas, Naomi B., additional, Yan, Hongxia, additional, Esquibel, Vanessa, additional, Rangwala, Reshma A., additional, and Campbell, Matthew T, additional

Published
2022
Full Text
View/download PDF

49. Healthcare resource utilization (HCRU) and costs for patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (LOT1) pembrolizumab plus axitinib (P+A) or ipilimumab plus nivolumab (I+N).

Author

Shah, Neil J., primary, Shinde, Reshma, additional, Moore, Kristin, additional, Sainski-Nguyen, Amy, additional, Le, Lisa, additional, Cao, Feng, additional, Song, Rui, additional, Singhal, Puneet, additional, and Motzer, Robert J., additional

Published
2022
Full Text
View/download PDF

50. A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140).

Author

Beckermann, Katy, primary, Shah, Neil J., additional, Vogelzang, Nicholas J., additional, Mao, Shifeng S., additional, Ornstein, Moshe Chaim, additional, Hammers, Hans J., additional, Gao, Xin, additional, McDermott, David F., additional, Haas, Naomi B., additional, Yan, Hongxia, additional, Esquibel, Vanessa, additional, Rangwala, Reshma A., additional, and Campbell, Matthew T, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results